Joseph Truitt
Patrimonio netto: 8 786 $ in data 30/09/2026
Patrimonio netto: 8 786 $ in data 30/09/2026
Joseph Truitt is Chief Executive Officer & Director at iECURE, Inc. since 2021.
Mr. Truitt is Chairman at Larimar Therapeutics, Inc. since 2020.
Mr. Truitt is Director at Code Biotherapeutics, Inc. since 2020.
Mr. Truitt is Independent Director at Century Therapeutics, Inc. starting 2026.
Formerly, Mr. Truitt was Chief Executive Officer & Director at BioSpecifics Technologies Corp.
in 2020.
Mr. Truitt was President, Chief Executive Officer & Director at Achillion Pharmaceuticals, Inc. from 2018 to 2020.
Mr. Truitt was Vice President-Sales & Operations at Johnson & Johnson in 2006.
Mr. Truitt was Vice President-Sales & Operations at OraPharma, Inc. in 2002.
Mr. Truitt was VP-Business Development & Product Strategy at Lev Pharmaceuticals, Inc. from 2007 to 2008.
Education includes undergraduate degree from LaSalle University and MBA from St. Joseph's University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 19/05/2026 | 2.750 ( 0% ) | 8 786 $ | 30/09/2026 | |
| 09/09/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Presidente | 28/05/2020 |
| CENTURY THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 09/09/2026 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Direttore/Membro del Consiglio | 01/12/2020 |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage biotechnology company that develops in-vivo gene insertion/editing therapies to treat rare liver disorders | Amministratore Delegato | 01/03/2021 |
| Società | Posizione | Fine |
|---|---|---|
| BIOSPECIFICS TECHNOLOGIES CORP. | Amministratore Delegato | 02/12/2020 |
| ACHILLION PHARMACEUTICALS, INC. | Amministratore Delegato | 28/01/2020 |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Corporate Officer/Principal | 01/12/2008 |
| JOHNSON & JOHNSON | Direttore operativo | 01/07/2006 |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces drugs for oral diseases | Direttore operativo | 01/01/2002 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
Johnson & Johnson
Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. Pharmaceuticals: MajorHealth Technology Develops injectable collagenase clostridium histolyticum (CCH) for multiple indications | Health Technology |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces drugs for oral diseases | Health Technology |
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
LaSalle University
LaSalle University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Joseph's University
St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Health Technology |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company focused on developing treatments for complex rare diseases | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage biotechnology company that develops in-vivo gene insertion/editing therapies to treat rare liver disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale